# Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment

> **NCT01613690** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Renal Impairment

## Interventions

- **DRUG:** NVA237

## Key facts

- **NCT ID:** NCT01613690
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01613690

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01613690, "Comparing the Pharmacokinetics, Safety and Tolerability of NVA237 in Renal Impairment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01613690. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*